학술논문

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Document Type
Article
Author
Bottomley, A.Coens, C.Mierzynska, J.Marreaud, S.Kicinski, M.Suciu, S.Blank, C.U.van Akkooi, A.C.J.Mandalà, M.Long, G.V.Atkinson, V.G.Dalle, S.Haydon, A.M.Meshcheryakov, A.Khattak, A.Carlino, M.S.Sandhu, S.Puig, S.Ascierto, P.A.Larkin, J.Lorigan, P.C.Rutkowski, P.Schadendorf, D.Koornstra, R.Hernandez-Aya, L.Di Giacomo, A.M.van den Eertwegh, A.J.M.Grob, J.-J.Gutzmer, R.Jamal, R.Krepler, C.Ibrahim, N.Robert, C.Eggermont, A.M.M.Lesimple, T.Maio, M.Linette, G.Mortier, L.Svane, I.M.Schachter, J.Brown, M.Hersey, P.Barrow, C.Kudchadkar, R.Dutriaux, C.Song, X.Quaglino, P.Queirolo, P.Meier, F.Stroyakovskiy, D.Guillot, B.Romero, P.L.O.Bastholt, L.Garbe, C.Grange, F.Mohr, P.Algazi, A.Bechter, O.Hernberg, M.Loquai, C.Meiss, F.Chiarion Sileni, V.Bar-Sela, G.Fitzharris, B.Saiag, P.Arnault, J.-P.Simon, J.-C.Stephens, R.Baurain, J.-F.Lebbe, C.Combemale, P.Dummer, R.Hauschild, A.Parente, P.Yamazaki, N.Milhem, M.Leccia, M.-T.Geoffrois, L.Kretschmer, L.Dunwoodie, E.Walker, J.Lotem, M.Hendler, D.Mackiewicz, A.Sekulovic, L.Dzienis, M.Hospers, G.A.P.Siano, M.Hassel, J.Corrie, P.Passos, M.-J.Levin, M.Hoeller, C.Machet, L.Hallmeyer, S.Waterston, A.Descamps, V.Kiecker, F.Aarts, M.Schmidt, H.Raimundo, A.Nyakas, M.Lacour, J.-P.Berking, C.Ferrucci, P.F.Jameson, M.Kim, K.Yokota, K.Kerger, J.Aubin, F.Groenewegen, G.Kapiteijn, H.Boehncke, W.-H.Utikal, J.Casasola, R.Marshall, E.Ferraresi, V.Richtig, E.Matkovic, S.Inozume, T.Crook, T.McNeil, C.Kiyohara, Y.Avril, M.-F.Hein, R.Terheyden, P.Nathan, P.Aoi, J.Skytta, T.Jouary, T.Takenouchi, T.Straume, O.Martins, C.Mukhametshina, G.
Source
In: The Lancet Oncology. (The Lancet Oncology, May 2021, 22(5):655-664)
Subject
Language
English
ISSN
14745488
14702045